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Abstract
The ADP-activated P2Y1 receptor is broadly expressed and plays a crucial role in ADP-promoted
platelet aggregation. We previously synthesized 2-iodo-N6-methyl–(N)-methanocarba-2′-
deoxyadenosine 3′,5′-bisphosphate (MRS2500), as a selective, high affinity, competitive
antagonist of this receptor. Here we report utilization of a trimethylstannyl precursor molecule for
the multistep radiochemical synthesis of a [125I]-labeled form of MRS2500. [125I]MRS2500
bound selectively to Sf9 insect cell membranes expressing the human P2Y1 receptor but did not
specifically bind to membranes isolated from empty vector-infected cells. Binding of
[125I]MRS2500 to P2Y1 receptors was saturable with a Kd of 1.2 nM. Known agonists and
antagonists of the P2Y1 receptor inhibited [125I]MRS2500 binding to P2Y1 receptor-expressing
membranes with potencies in agreement with those previously observed in functional assays of
this receptor. A high-affinity binding site for [125I]MRS2500 also was observed on intact human
platelets (Kd = 0.61 nM) and mouse platelets (Kd = 1.20 nM) that exhibited the pharmacological
selectivity of the P2Y1 receptor. The densities of sites observed were 151 sites/platelet and 229
sites/platelet in human and mouse platelets, respectively. In contrast, specific binding was not
observed in platelets isolated from P2Y1 receptor (−/−) mice. Taken together, these data illustrate
the synthesis and characterization of a novel P2Y1 receptor radioligand and its utility for
examining P2Y1 receptors natively expressed on human and mouse platelets.
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A broad range of physiological responses are promoted by extracellular nucleotides
signaling through two classes of cell surface receptors [1]. The P2X receptors are ATP-
activated ion channels, and the P2Y receptors are G protein-coupled receptors that are
activated by ATP, UTP, ADP, UDP, or nucleotide sugars. The P2Y receptor family includes
eight receptor subtypes [2]. The P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors activate
Gαq/phospholipase C, and therefore, these receptors primarily signal through the inositol
lipid signaling cascade. The P2Y12, P2Y13, and P2Y14 receptors activate Gi resulting in
inhibition of adenylyl cyclase as well as G protein-dependent activation of ion channels.
The ADP-activated P2Y1 receptor is relatively broadly expressed in brain and peripheral
tissues [3]. This signaling protein fulfills an obligatory role in ADP-promoted platelet
aggregation by triggering shape change and an initial, reversible phase of aggregation. Study
of the P2Y1 receptor on platelets and other tissues has been augmented by identification of
selective antagonists and agonists for this receptor. Adenosine 3′,5′-bisphosphate was
identified as the first selective P2Y1 receptor antagonist [4] and was utilized to resolve
pharmacologically the relative actions of the ADP-activated P2Y1 receptor versus the ADP-
activated P2Y12 receptor in platelet aggregation [5, 6]. Subsequent medicinal chemistry has
focused on developing higher affinity non-nucleotide P2Y1 receptor antagonists [7, 8], and
on generation of a high affinity P2Y1 receptor agonist that activates the P2Y1 receptor but
not the ADP-activated P2Y12 or the ADP-activated P2Y13 receptor [9, 10] .
Mechanism(s) associated with both the function and the regulation of the P2Y1 receptor in
platelets and other tissues are not fully understood. For example, the platelet P2Y1 receptor
rapidly desensitizes [9, 11] and internalizes [12] but molecular understanding of these
phenomena is lacking. Polymorphisms have been identified in the P2Y1 receptor gene, and
several of these have been proposed to be associated with an increased risk of cardiovascular
disease [13-17]. However, the molecular basis of such an association remains undefined.
An increase in molecular understanding of the P2Y1 receptor could be provided by
application of a radioligand that allowed unambiguous quantification of the density, cellular
distribution, and ligand binding properties of the receptor, and an important goal of our
research is to identify such a molecule. The non-nucleotide antagonist, 2-iodo-N6-methyl-
(N)-methanocarba-2′-deoxyadenosine-3′5′-bisphosphate (MRS2500) exhibits the highest
apparent affinity (Ki ~ 1 nM) reported to date for an antagonist of the P2Y1 receptor [8], and
we previously synthesized a [32P]-labeled form of this molecule and applied it for
quantification of P2Y1 receptors in rat tissues [18]. However, the short half-life of 32P as
well as inefficient and variable incorporation of 32P into the precursor molecule led us to
consider synthesis of [125I]MRS2500 utilizing iododestannylation of an stannyl aryl
intermediate as previously described for preparation of several other radioiodinated ligands
[19, 20]. A direct one-step reaction was not suitable for production of MRS2500, and
therefore, a synthetic route was modified to a 3-step radiochemical synthesis. We report here
the binding properties of [125I]MRS2500, establishing it as an optimized radioligand for
study of recombinant P2Y1 receptors and P2Y1 receptors natively expressed on human and
mouse platelets.
2. Materials and methods
2.1. Chemical synthesis
2.1.1. Materials and instrumentation—Hexamethyltin, 1.0 M tetrabutylammonium
dihydrogen phosphate, 32% peracetic acid, and other reagents were purchased from Sigma-
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Aldrich Chemical Co. (St. Louis, MO), except where noted. Sodium [125I]iodide (17.4 Ci/
mg) in NaOH (1.0 × 10−5 M) was supplied by Perkin–Elmer Life and Analytical
Science. 1H NMR spectra were obtained with a Varian Gemini 300 spectrometer using
CDCl3 as solvent. Chemical shifts are expressed in δ values (ppm) with tetramethylsilane (δ
0.00). TLC analysis was carried out on aluminum sheets with silica gel F254 (0.2 mm) from
Aldrich. HPLC mobile phases for the nonradioactive synthesis consisted of System A: linear
gradient solvent system: CH3CN/triethylammonium acetate (10 mM) from 5/95 to 60/40 in
20 min, flow rate 1.0 ml/min; System B: linear gradient solvent system: CH3CN/tetrabutyl
ammonium phosphate (5 mM) from 20/80 to 60/40 in 20 min, flow rate 1.0 ml/min. HPLC
mobile phases for the radioactive synthesis consisted of System C: linear gradient solvent
system: CH3CN/tetrabutylammonium phosphate (5 mM) from 0/100 to 10/90 in 0.1 min,
10/90 to 30/70 in 5 min, 30/70 to 100/0 in 20 min, flow rate 1.0 ml/min; system D: linear
gradient solvent system: CH3OH/triethylammonium acetate (10 mM, pH 7) at 0/100 for 1-2
min and then 5/95 to 15/85 in 40 min, flow rate 1.0 ml/min. Column A was Luna 5 μ C18(2)
HPLC column from Phenomenex, Inc., Torrence, CA. Column B was 5 μ, C18 HPLC
column from MAC-MOD Analytical, Inc., Chadd’s Ford, PA.
2.1.2. Strategy for chemical synthesis—We previously reported that [32P]MRS2500
is a useful radioligand for quantification of P2Y1 receptors [18]. With the goal of generating
a [125I]-labeled form of this molecule and after trying several abortive routes (Fig. 1A and
B), we synthesized a trimethylstannyl analogue 6 (MRS2829) that potentially could be
radio-iodinated as illustrated in Fig. 1C and D. The protected [125I]-labeled derivative 7
could be deprotected in TFA to yield 8 and then converted to [125I]MRS2500 9 via N6-
methylation by nucleophilic attack with MeNH2.
2.1.3. Synthesis of (1′R,2′S,4′S,5′S)-phosphoric acid di-tert-butyl ester 1-(di-
tert-butoxy-phosphoryloxymethyl)-4-(6-chloro-2-trimethylstannylpurin-9-
yl)bicyclo[3.1.0]hex-2-yl ester (6, MRS2829)—The iodo derivative 5 was prepared as
previously described [21]. Me3SnSnMe3 (20 mg, 0.061 mmol) was added to a solution of 5
(2.7 mg, 0.0034 mmol) and PdCl2(PPh3)2 (3.5 mg, 0.0050 mmol) in dioxane (0.30 ml), and
the mixture stirred at 60 °C for 3.5 h. The solvent was removed under vacuum and the
residue was purified by TLC (AcOEt), which furnished the stannyl derivative 6 (0.6 mg,
23%): 1H NMR (CDCl3) 8.54 (s, 1H), 5.40-5.36 (m, 2H), 4.76 (m, 1H), 4.00 (m, 1H), 2.49
(m, 1H), 2.29 (m, 1H), 1.95 (m, 1H), 1.60 (s, 9H), 1.36 (s, 18H), 1.15 (m, 1H), 0.99 (m, 1H),
0.54 (s, 9H); MS (m/e) (positive-FAB): for C35H65ClN4O9P2Sn+ (M + tBuOH) 902.2937,
found 902.2962. HPLC 3.71 min (90%) in solvent System A, 2.86 min (90%) in System B.
2.1.4. Small-scale conversion of compound 6 into compound 5—The formation
of 5 from 6 (Fig. 1C) was piloted on a small scale with the goal of optimizing this reaction
for production of 5 in a [125I]-labeled form. The trimethylstannyl intermediate 6 (0.1 mg)
was reconverted to the iodo derivative 5 upon dissolving in MeOH (0.1 ml) followed by
treatment with I2 (0.1 M in MeOH, 0.1 ml) for 10 min at room temperature. The structure 5
was confirmed by mass spectroscopy. MS (m/e) (positive-FAB): for C32H56ClIN4O9P2+ (M
+ tBuOH) 864.2256, found 864.2256.
2.1.5. Radiochemical synthesis of (1′R,2′S,4′S,5′S)-phosphoric acid di-tert-
butyl ester 1-(di-tert-butoxy-phosphoryloxymethyl)-4-(6-chloro-2-[125I]iodo-9H-
purin-9-yl)bicyclo[3.1.0]hex-2-yl ester (7)—A solution of the stannyl derivative
MRS2829 6 in acetonitrile (25 μl, corresponding to 25 μg, 30 nmol) was added to ~80 μl
Na125I solution (55 mCi, 25 nmol) in a glass container. A mixture of 32% peracetic acid/
acetonitrile/glacial acetic acid was prepared in the ratio of 5/85/10 (v/v), and 2.5 μl of this
peracetic acid solution (40 μg, 525 nmol) was added to the reaction mixture with brief
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mixing. After 10 min, the reaction mixture was diluted with 0.3 ml water, and the entire
quantity was injected onto the HPLC (System C, Column B) to yield 8.8 mCi (32% yield) of
7 at 24 min. For confirmation of the identity of the radioactive product, a coinjected mixture
of 5 and 7 eluted as a single peak
2.1.6. Radiochemical synthesis of [125I]MRS2500 (9)—The solution of [125I]7 was
concentrated to dryness under vacuum, and the residue was treated with 200 μl
trifluoroacetic acid with brief mixing followed by incubation at room temperature for 5 min.
The reaction mixture was concentrated to dryness under vacuum. The residue was treated
with 100 μl of 40% aqueous methylamine with brief mixing and incubation at room
temperature for 5 min. Water (0.3 ml) was added, and this solution was injected onto the
HPLC as above (System C, Column B). A peak containing 7.5 mCi was collected (85% and
26% radiochemical yield for the two steps). For confirmation of the identity of the
radioactive product, coinjection of the unlabeled intermediate 8, unlabeled MRS2500, and
labeled 9 resulted in elution of a chloride peak at 11 min without radioactivity and a
radioactive MRS2500 peak at 14 min. The specific activity of the purified radioligand was
81 TBq (2200 Ci/mmol).
2.2. Pharmacological analyses
2.2.1. Materials—Apyrase was purified from potatoes as previously described [22].
ARC69931MX (Cangrelor) was provided by the Medicines Co. (Parsippany, NJ). MRS2179
and MRS2365 were from Tocris (Bristol, UK). ADP was from Boehringer (Mannheim,
Germany). All other drugs were from Sigma-Aldrich Corporation (St. Louis, MO).
2.2.2. P2Y1 receptor expression in Sf9 insect cells—Membranes were prepared
from Sf9 insect cells expressing the recombinant human P2Y1 receptor as described in detail
previously [23]. Briefly, suspension cultures of Sf9 insect cells grown to a density of 1.4 ×
106 cells/ml were infected with empty vector or recombinant baculovirus encoding the
human P2Y1 receptor. Cells were harvested after two days by low speed centrifugation, and
the cells were lysed using a Parr cavitation apparatus. A membrane fraction was isolated by
high speed centrifugation, and the membranes were resuspended at a concentration of ~ 3.5
mg/ml in 20 mM Tris, pH 8.0, 250 mM sucrose, 2 mM 2-mercaptoethanol, 100 μg/ml
phenylmethanesulphonylfluoride, 100 μM benzamidine, and 50 μg/ml tosylphenylalanyl
chloromethyl ketone. Membranes were stored at −80°C and diluted approximately 300-fold
for binding assays as described below.
2.2.3. Preparation of washed platelet suspension—Washed platelets from human or
mouse blood were prepared by differential centrifugation as previously described [22].
Platelets were suspended in Tyrode’s buffer (137 mM NaCl, 2 mM KCl, 12 mM NaHCO3,
0.3 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM glucose, 5 mM HEPES, pH 7.3)
containing 0.35% human serum albumin and apyrase (0.02 U/ml), which degrades released
ADP and prevents desensitization. Human platelets were maintained at a concentration of
300,000 platelets/μl at 37°C, and mouse platelets were maintained at a concentration of
150,000 platelets/μl at 37°C. Three different donors were utilized for isolation of three
different preparations of platelets for each experiment.
2.2.4. Radioligand binding assay with recombinant P2Y1 receptors—Assays
with membranes isolated from P2Y1 receptor-expressing Sf9 insect cells typically were with
0.2-0.5 nM [125I]MRS2500 and 100-300 ng of membranes in assay buffer (20 mM HEPES,
145 mM NaCl, 5 mM MgCl2, pH 7.5) in a total volume of 25 μl. All incubations were
carried out in 12 × 75 mm conical tubes at 4° C and were terminated after 30 min by the
addition of 3.5 ml of ice cold assay buffer followed by vacuum filtration over Whatman GF/
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A glass microfiber filters. The filters were washed with 7 ml of ice-cold assay buffer and
radioactivity on each filter was quantified in a gamma counter. Specific binding was defined
as total [125I]MRS2500 bound minus binding occurring in the presence of 30 μM
2MeSADP or 10 μM MRS2179.
2.2.5. Radioligand binding assay with human and mouse platelets—
[125I]MRS2500 binding assays with intact washed platelets were performed at 20°C or
37°C. Assays with washed human platelets were initiated by addition of 900 μl of platelet
suspension to a final volume of 1 ml of Tyrode’s buffer containing albumin. Assays with
washed mouse platelets were initiated by addition of 400 μl of platelet suspension to a final
volume of 0.5 ml of Tyrode’s buffer containing albumin. Steady state binding was attained
within 5 min at 20°C or 37°C, and therefore, binding reactions were terminated after 5 min
by vacuum filtration through GF/C glass fiber filters followed by five rapid washes with 3
ml of ice-cold Tyrode’s buffer. Radioactivity was quantified in a gamma counter. Specific
binding was defined as total [125I]MRS2500 bound minus binding occurring in the presence
of 10 μM MRS2179. Association, saturation, and competition binding experiments were
performed using a single concentration of radiolabeled ligand (25 pM, 65,000 cpm/tube of 1
ml reaction mixture) in the presence of increasing concentrations of the appropriate
unlabeled ligand.
2.2.6. Data Analysis—Data were analyzed using GraphPad Prism (GraphPad Software,
San Diego, CA). The results are presented as the mean ± S.E.M. averaged from three or
more experiments or in some cases as a data set from a single experiment that was typical of
results from three or more experiments.
3. Results
3.1. Synthesis of [125I]MRS2500 and strategy for its application in a radioligand binding
assay
We previously illustrated that iodo-substitution in a series of halo-substituted (N)-
methanocarba bisphosphate analogues resulted in a competitive antagonist (MRS2500) that
exhibited high affinity (Ki ~1 nM) and a high degree of binding selectivity for the P2Y1
receptor [8]. A monophosphate precursor of this high affinity antagonist was synthesized
and conditions optimized for its [32P]phosphorylation using nucleotide kinase and
[γ32P]ATP [18]. [32P]MRS2500 proved to be an excellent radioligand for quantification of
both recombinant and natively expressed P2Y1 receptors. However, the short half-life of 32P
as well as somewhat inefficient incorporation of 32P into the precursor molecule led us to
consider alternative means of production of radiolabelled MRS2500.
We tried three different approaches for establishing a successful 3-step route from a stable
stannylated intermediate 6. Two unsuccessful approaches to the synthesis of [125I]MRS2500
are shown in Figures 1A and B. The direct stannylation of MRS2500 1 gave an intermediate
2 that proved to be unstable. Although compound 2 was detected by HPLC, it was not
sufficiently stable even when stored at low temperature (−80°C), and thus, it could not be
purified. Alternatively, the attempted stannylation of 3, a phosphate-protected form of
MRS2500, with trimethyltin under the same conditions gave only the undesired compound
4. This occurred upon replacement of the trimethylstannyl group by hydrogen readily
available from acidic protons such as the 6-NHMe in the reaction [8]. Finally, a
trimethylstanno derivative 6 was synthesized (Fig. 1C) from 5 by the method of
Baranowska-Lortylewicz and coworkers with hexamethylditin in the presence of
bis(triphenylphosphine)palladium(II) dichloride in dioxane for 3.5 h at 60 °C [24].
Intermediate 6 was intended for conversion to the iodo-form of 1 by a multi-step process to
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deprotect the phosphate groups and to exchange the functionality at the 6 position.
Feasibility of the rapid re-conversion of 6 to an iodinated precursor 5 was demonstrated on
small scale. We then took advantage of this procedure to produce a 125I-labeled precursor of
MRS2500 7, which was purified by HPLC (Fig. 1D). The radiochemical yield for the
conversion of 6 to 7 was 35%, including HPLC purification.
This radiolabeled molecule was deprotected to produce the intermediate 8, which in turn
was converted to [125I]MRS2500 9 via N6-methylation by nucleophilic attack with
methylamine. The final product 9 was purified by HPLC. It was also possible to combine the
last two chemical steps successively in one pot (i.e., it was not necessary to purify 8). Using
this procedure, 163 MBq (4.4 mCi) of [125I]MRS2500 was prepared. The overall
radiochemical yield for the two steps from 7 to 9 was 23%, including HPLC purification.
3.2. Pharmacological analyses
3.2.1. Strategy—The approach utilized to examine [125I]MRS2500 as a potential
radioligand for quantification of P2Y1 receptors included two different sources of P2Y1
receptors. First, we examined the binding properties of [125I]MRS2500 at human P2Y1
receptors in membranes prepared from Sf9 insect cells expressing recombinant receptor at
high levels. Second, the P2Y1 receptor serves an obligatory physiological role in the effects
of ADP on platelet shape change and aggregation [3]. Therefore, with the ultimate goal of
applying an optimized radioligand for molecular study of the platelet P2Y1 receptor, we
examined the properties of [125I]MRS2500 binding using human and mouse platelets.
3.2.2. Binding of [125I]MRS2500 to recombinant human P2Y1 receptors—We
previously generated a baculovirus expression vector that harbors the coding sequence of the
human P2Y1 receptor. Infection of Sf9 insect cells with this baculovirus results in high level
expression (~10 pmol/mg protein) of active P2Y1 receptor [23], and this system has been
used as a source for purification of the human P2Y1 receptor to homogeneity [25]. As
illustrated in Fig. 2, incubation of [125I]MRS2500 with membranes from wild-type insect
cells resulted in no specific binding of radioligand over a wide range of membrane
concentrations. In contrast, specific binding of [125I]MRS2500 was detected with as little 30
ng of membranes prepared from cells infected with P2Y1 receptor baculovirus. Binding of
[125I]MRS2500 increased linearly with protein concentration up to 1 μg per assay at a
concentration of radioligand of approximately 0.3 nM. Time course experiments (data not
shown) revealed that steady state binding was obtained within 20 min in assays carried out
with approximately 0.3 nM of [125I]MRS2500 and 300 ng of membranes, and a steady-state
was maintained for at least 40 min.
Saturation binding of [125I]MRS2500 was quantified over a wide range (0.04 nM to 5.15
nM) of concentrations. The resultant binding isotherm and transformation of these data
using the Scatchard equation are presented in Fig. 3. Specific binding of [125I]MRS2500
exhibited one-site binding kinetics with a Kd of 1.1 ± 0.3 nM observed. The Bmax obtained
for P2Y1 receptor expression in Sf9 cells was 13.3 ± 2.2 pmol/mg membrane protein.
Competition curves were generated with a series of adenine nucleotides and analogues
known to interact with the P2Y1 receptor (Fig. 4). The highest apparent affinity was
observed with 2MeSADP (Ki = 70 ± 30 nM), followed in relative affinities by ADP (Ki =
625 ± 37 nM), ADP!S (Ki = 1750 ± 750 nM), and ATP (Ki = 16,250 ± 875 nM). UTP had
no effect on [125I]MRS2500 binding at concentrations up to 30 μM.
3.2.3. Binding of [125I]MRS2500 to P2Y1 receptors on human platelets—We also
examined the capacity of [125I]MRS2500 to interact with binding sites on human platelets.
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Incubation of [125I]MRS2500 with platelets over a range of concentrations up to 300,000
platelets/μl resulted in an essentially linear increase in the amount of radioligand bound
(Fig. 5). In contrast, very little [125I]MRS2500 binding was observed in the presence of the
selective P2Y1 receptor antagonist MRS2179 (10 μM). Time course experiments at 37°C
revealed that binding reached apparent steady state within 60-90 sec, and [125I]MRS2500
binding was stable for at least 15 min (data not shown). All subsequent assays were carried
out using 5 min incubations.
The concentration of [125I]MRS2500 was varied from 0.025 nM to 10 nM as described in
Methods, and specific binding was assessed as a function of radioligand concentration at
37°C. The resultant binding isotherm and transposition of these data using the Scatchard
equation are presented in Fig. 6. Specific binding of [125I]MRS2500 to human platelets
exhibited one-site binding kinetics with Kd = 0.61 ± 0.03 nM and a Bmax of 151 ± 1 sites/
platelet. Saturation binding isotherms generated for human platelets at 20°C (data not
shown) also were consistent with interaction with a single population of binding sites with
Kd = 0.25 nM and 147 sites/platelet. Since all assays were carried out in the presence of
apyrase, which degrades any released ADP, the binding values obtained were not influenced
by events associated with agonist-induced desensitization.
The capacity of agonists and antagonists of the P2Y1 receptor to inhibit [125I]MRS2500
binding to human platelets also was determined (Fig. 7). The antagonists MRS2179 and
MRS 2500 inhibited radioligand binding in concentration dependent fashion, and the higher
apparent affinity of MRS2500 (Ki = 1.20 ± 0.15 nM) compared to MRS2179 (Ki = 72.5 ±
17 nM) is consistent with the reported activities of these molecules. As also is predicted
from previous studies, the synthetic agonist analogue 2MeSADP (Ki = 46.5 ± 1.7 nM) was
more potent than the cognate agonist of the P2Y1 receptor, ADP (Ki = 15.4 ± 9 μM). Little
effect of the P2Y12 receptor antagonist ARC-69931MX or P2X receptor agonist !!MeATP
on [125I]MRS2500 binding was observed at concentrations of competing drugs up to 100
μM.
3.2.4. Binding of [125I]MRS2500 to P2Y1 receptors on mouse platelets—We also
investigated [125I]MRS2500 as a potential radioligand for quantification of P2Y1 receptors
on mouse platelets. As was observed with human platelets, [125I]MRS2500 binding
increased linearly with increasing amounts of mouse platelets up to 200,000 platelets/μl
(Fig. 8A). Whereas binding was inhibited by the P2Y1 receptor agonists ADP, 2MeSADP,
and MRS2365 and the antagonist MRS2179, no effect was observed with the P2Y12
receptor antagonist ARC-69931MX (Fig 8B). Importantly, total binding of [125I]MRS2500
was much lower in platelets isolated from P2Y1(−/−) mice, and this low amount of binding
was not inhibited by a high concentration of 2MeSDP. Thus, specific binding of
[125I]MRS2500 was not observed in platelets isolated from P2Y1(−/−) mice, and both
pharmacological and genetic data with mice platelets are consistent with the idea that
[125I]MRS2500 specifically labels the P2Y1 receptor.
Saturation binding experiments also were carried out with platelets isolated from wild-type
mice. The binding isotherm and transposition of these data using the Scatchard equation are
presented in Fig. 9. Specific binding of [125I]MRS2500 to mouse platelets exhibited single
site binding kinetics (Kd = 1.2 ± 0.1 nM) in saturation binding assays carried out at 37°C
(Fig. 9), and a Bmax of 229 ± 23 sites/platelet was determined. Similar values (Kd = 0.5 nM
and Bmax = 253 sites/platelet) were obtained in saturation binding assays carried out at
20°C (data not shown).
Ohlmann et al. Page 7














One of our research goals in drug development in recent years has been to develop an
opitimized radioligand for direct quantification of the P2Y1 receptor. MRS2179 was one of
the first synthetic antagonists to show high selectivity for the P2Y1 receptor [26], and
although this molecule exhibits intermediate affinity (Kd ~100 nM) for this receptor, a
[33P]-labeled form was used to detect P2Y1 receptors on human platelets [27]. MRS2279
was synthesized as a non-nucleotide P2Y1 receptor antagonist of higher affinity (Kd ~ 10
nM) that also exhibited high selectivity for the P2Y1 receptor over other P2Y receptors.
[3H]2-chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate
([3H]MRS2279) provided the first widely applied radioligand for study of the P2Y1 receptor
[23, 25]. We subsequently synthesized a non-nucleotide antagonist, 2-iodo-N6-methyl-(N)-
methanocarba-2′deoxyadenosine-3′5′-bisphosphate (MRS2500), that inhibited
[3H]MRS2279 binding to the P2Y1 receptor with a Ki value (~ 1 nM) ten times lower than
that of MRS2279 [8]. More recently, a precursor of this molecule was synthesized that
allowed facile, single-step kinase-catalyzed [32P]phosphorylation of a precursor molecule to
yield [32P]MRS2500 [18]. This radioligand in turn was shown to bind selectively to the
P2Y1 receptor versus other P2Y receptors and was utilized to quantify P2Y1 receptors
natively expressed in rat brain and several other tissues. The binding characteristics of
[32P]MRS2500 were excellent [7, 18], but the relatively low yield using enzymatic synthesis
of the radioligand introduced limitations.
The chemistry described here takes advantage of a trimethylstannyl analogue 6 that allows
facile synthesis of [125I]MRS2500. Only a few examples of direct iododestannylation on
unprotected nucleotides exist, and there are no positions for straightforward incorporation of
iodine into MRS2500. Our initial attempts to carry out iododestannylation in one or two
steps failed. The successful synthetic route described here required three radiochemical
steps, which otherwise would not be considered optimal because of the limitations of
handling radioactive intermediates. However, each of these steps was carried out in a small
volume and with high yield without excessive manipulation. Therefore, it constitutes a
practical and efficient method, but one that requires nonaqueous reaction conditions for one
step, i.e., the phosphate deprotection.
Given our previous success with application of [32P]MRS2500 in radioligand binding assays
[18], it is not surprising that the [125I]-labeled form of this molecule also proves an
outstanding radio-probe for quantification of P2Y1 receptors with a radioligand of relatively
long radioactive half-life. The most well-established physiological function of this receptor
involves its role with the P2Y12 receptor coordinating the shape change and aggregation
response that occurs in platelets in response to ADP [3]. The data presented here establish
radioligand binding assays with [125I]MRS2500 as a means to directly quantify and study
native P2Y1 receptors on the cell surface of intact human and mouse platelets.
Methodology for quantification of P2Y1 receptor binding sites is crucial for advancing our
understanding of a variety of conditions. For example, the platelet P2Y1 receptor rapidly
desensitizes during agonist activation [9, 11, 12], but the molecular mechanisms that
underpin this loss of responsiveness remain undefined. Similarly, polymorphisms of the
P2Y1 receptor have been proposed to be associated with an increased risk of cardiovascular
disease [13-17], but the relative densities and binding properties of the platelet P2Y1
receptor associated with these polymorphisms is not known. The studies reported here
establish [125I]MRS2500 as a valuable new radioligand to investigate mechanistic aspects of
the P2Y1 receptor in these and other conditions.
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Figure 1. Attempted approaches to the synthesis of [125I]MRS2500
A, By direct stannylation of MRS2500. Intermediate 2 proved to be unstable. B, By direct
stannylation of 3, a phosphate-protected form of MRS2500. Instead of the desired stannyl
intermediate, only the 2-H compound 4 was obtained. C, By stannylation of 5, a phosphate-
protected precursor of MRS2500, to which the 6-methylamino group is to be added later by
substitution of a 6-chloroadenine group. The 2-trimethylstannyl intermediate 6 was
synthesized and the feasibility of its re-conversion to an iodinated precursor of MRS2500 5
was demonstrated. D, The optimized, successful radiochemical synthesis, as described in
Methods. [125I]MRS2500 9 was synthesized via [125I]-labeling of 6 to produce intermediate
7, deprotection of phosphates of 7 with TFA to produce the 6-chloro intermediate 8, and N6-
methylation with methylamine to produce 9.
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Figure 2. Binding of [125I]MRS2500 to membranes from Sf9 insect cells expressing recombinant
human P2Y1 receptors
[125I]MRS2500 was incubated with the indicated amounts of membranes prepared from Sf9
insect cells infected with empty baculovirus (WT-Sf9) or human P2Y1 receptor baculovirus
(P2Y1-Sf9) as described in Methods. Assays were in the absence (closed symbols) or
presence (open symbols) of 30 μM 2MeSADP.
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Figure 3. Saturation binding of [125I]MRS2500 to membranes from Sf9 insect cells expressing
recombinant human P2Y1 receptors
Top panel, P2Y1 receptor-expressing membranes were incubated with the indicated
concentrations of [125I]MRS2500 in the absence (■) or presence (▲) of 30 μM 2MeSADP
as described in Methods. Bottom panel, The data presented in the top panel were plotted as
the amount (fmol) of [125I]MRS2500 specifically bound on the X-axis versus the amount
bound divided by the free concentration of [125I]MRS2500 on the Y-axis.
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Figure 4. Inhibition of [125I]MRS2500 binding to P2Y1 receptor-expressing membranes by P2Y1
receptor agonists
Membranes prepared from Sf9 insect cells infected with human P2Y1 receptor baculovirus
were incubated with [125I]MRS2500 and the indicated concentrations of 2MeSADP (■),
ADP (▲), ADPβS (▼), ATP (◆), or UTP (●) as described in Methods.
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Figure 5. Binding of [125I]MRS2500 to human platelets
Platelet concentrations ranging from 50,000 platelets/μl to 750,000 platelets/μl were
incubated with [125I]MRS2500 at 37°C in the absence (■) or presence (▲) of 10 μM
MRS2179 as described in Methods.
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Figure 6. Saturation binding of [125I]MRS2500 to human platelets
Top panel, Human platelets were incubated with the indicated concentrations of
[125I]MRS2500 at 37°C as is described in Methods. Specific binding (total binding minus
binding in the presence of 10 μM MRS2179) is plotted. Bottom panel, The data presented
in the top panel were plotted as the amount (fmol) of [125I]MRS2500 specifically bound on
the X-axis versus the amount bound divided by the free concentration of [125I]MRS2500 on
the Y-axis.
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Figure 7. Inhibition of [125I]MRS2500 binding to human platelets by P2Y1 receptor ligands
Platelets were incubated with [125I]MRS2500 and the indicated concentrations of MRS2500
(●), 2MeSADP (△), MRS2179 (▼), ADP (○), αβMeATP (□), or ARC-69931MX (x), as
described in Methods.
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Figure 8. Binding of [125I]MRS2500 to mouse platelets
Top panel, Platelet concentrations ranging from 50,000 platelets/μl to 200,000 platelets/μl
were incubated with 50 fmol of [125I]MRS2500 at 37°C in the absence (■) or presence (▲)
of 10 μM MRS2179 as described in Methods. Bottom panel, Platelets were prepared from
wild-type or P2Y1 (−/−) mice and incubated with [125I]MRS2500 in the absence of
additional drug (open bars) or with 100 μM ADP (gray bars), 10 μM 2MeSADP (squared
bars), 10 μM MRS2179 (black bars), 10 μM MRS2365 (cross-hatched bars), or 10 μM
ARC-69931MX (perpendicular-lined bars) as described in Methods.
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Figure 9. Saturation binding of [125I]MRS2500 to mouse platelets
Top panel, Mouse platelets were incubated with the indicated concentrations of
[125I]MRS2500 at 37°C as is described in Methods. Specific binding (total binding minus
binding in the presence of 10 μM MRS2179) is plotted. Bottom panel, The data presented
in the top panel were plotted as the amount (fmol) of [125I]MRS2500 specifically bound on
the X-axis versus the amount bound divided by the free concentration of [125I]MRS2500 on
the Y-axis.
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